Evidence map›Paper›PMID 35806060›Full record

ArticleInternational journal of molecular sciences2022

Computational Analysis Identifies Novel Biomarkers for High-Risk Bladder Cancer Patients.

Radosław Piliszek, Anna A Brożyna, Witold R Rudnicki

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Radosław PiliszekComputational Centre, University of Białystok, ul. Konstantego Ciołkowskiego 1M, 15-245 Białystok, Poland.ORCID 0000-0003-0729-9167
Anna A BrożynaDepartment of Human Biology, Institute of Biology, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, ul. Lwowska 1, 87-100 Toruń, Poland.ORCID 0000-0002-3195-9965
Witold R RudnickiComputational Centre, University of Białystok, ul. Konstantego Ciołkowskiego 1M, 15-245 Białystok, Poland.ORCID 0000-0002-7928-4944

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the case of bladder cancer, carcinoma in situ (CIS) is known to have poor diagnosis. However, there are not enough studies that examine the biomarkers relevant to CIS development. Omics experiments generate data with tens of thousands of descriptive variables, e.g., gene expression levels. Often, many of these descriptive variables are identified as somehow relevant, resulting in hundreds or thousands of relevant variables for building models or for further data analysis. We analyze one such dataset describing patients with bladder cancer, mostly non-muscle-invasive (NMIBC), and propose a novel approach to feature selection. This approach returns high-quality features for prediction and yet allows interpretability as well as a certain level of insight into the analyzed data. As a result, we obtain a small set of seven of the most-useful biomarkers for diagnostics. They can also be used to build tests that avoid the costly and time-consuming existing methods. We summarize the current biological knowledge of the chosen biomarkers and contrast it with our findings.

Indexed as

Carcinoma in SituUrinary Bladder NeoplasmsBiomarkersBiomarkers, TumorDisease ProgressionHumansNeoplasm InvasivenessUrinary BladderBiomarkersBiomarkers, Tumorbiomarker identificationcarcinoma in situ (CIS)nonmuscle-invasive bladder cancer (NMIBC)optimal feature set selection

Identifiers

PMID35806060
PMCPMC9266725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.